Parodis, I.; Adamichou, C.; Aydin, S. et al.
GLOMERULAR AND TUBULOINTERSTITIAL LESIONS IN PER-PROTOCOL REPEAT BUT NOT BASELINE KIDNEY BIOPSY PORTEND RELAPSE AND LONG-TERM RENAL FUNCTION IMPAIRMENT, RESPECTIVELY, IN INCIDENT CASES OF PROLIFERATIVE LUPUS NEPHRITISANNALS OF THE RHEUMATIC DISEASES. Bd. 79. 2020 S. 347-347
Längericht, J; Krämer, I; Kahaly, G
Glucocorticoids in Graves orbitopathy: mechanisms of action and clinical applicationTherapeutic Advances in Endocrinology and Metabolism. Bd. 11. 2020 S. 1-21
Ascher, Stefanie; Wilms, Eivor; Pontarollo, Giulia et al.
Gut Microbiota Restricts NETosis in Acute Mesenteric Ischemia-Reperfusion InjuryARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. Bd. 40. H. 9. 2020 S. 2279-2292
Ponto, Katharina A.; v. d. Osten-Sacken, Sara; Elflein, Heike et al.
Healthcare relevant data from an interdisciplinary consultation for endocrine orbitopathyOPHTHALMOLOGE. 2020
Hsu, Chiun; Ducreux, Michel; Zhu, Andrew X. et al.
HEPATIC EVENTS AND VIRAL KINETICS IN PATIENTS (PTS) WITH HEPATITIS B/C VIRUS (HBV/HCV)-RELATED, UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH ATEZOLIZUMAB (ATEZO) plus BEVACIZUMAB (BEV) OR SORAFENIB (SOR) IN IMbrave150HEPATOLOGY. Bd. 72. 2020 S. 779A-780A
Darstein, F.; Haeuser, F.; Mittler, J. et al.
Hepatitis E Is a Rare Finding in Liver Transplant Patients With Chronic Elevated Liver Enzymes and Biopsy-Proven Acute RejectionTRANSPLANTATION PROCEEDINGS. Bd. 52. H. 3. 2020 S. 926-931
Czauderna, Carolin; Schmidtmann, Irene; Koch, Sandra et al.
High pre-treatment static and dynamic alpha-fetoprotein values predict reduced overall survival in hepatocellular carcinoma2020
Fottner, C.; SoWank, S.; Ghiasi, M. et al.
Identification of a Novel MAFA Missense Mutation Causing Familial InsulinomatosisNEUROENDOCRINOLOGY. Bd. 110. 2020 S. 70-70
Rehberg, Markus; Giegerich, Clemens; Praestgaard, Amy et al.
Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial DataARTHRITIS & RHEUMATOLOGY. Bd. 72. 2020
Kudo, M.; Ikeda, M.; Zhu, A. X. et al.
IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCCANNALS OF ONCOLOGY. Bd. 31. 2020 S. S1304-S1305